Ambrx Biopharma Inc. Banner Image

Ambrx Biopharma Inc.

  • Ticker AMAM
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Ambrx Biopharma Inc. Logo Image
  • 51-200 Employees
  • Based in San Diego, California
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, includingMore ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. In addition, Ambrx has preclinical and clinical collaborations with multiple partners on drug candidates generated using Ambrx technology. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology. For more information, please visit www.ambrx.com. Ambrx routinely posts information that may be important to investors on its website.
Ambrx Biopharma Inc.

Most Recent Annual Report

Ambrx Biopharma Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Ambrx Biopharma Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!